118 related articles for article (PubMed ID: 21975067)
1. Binding of isoxazole and pyrazole derivatives of curcumin with the activator binding domain of novel protein kinase C.
Das J; Pany S; Panchal S; Majhi A; Rahman GM
Bioorg Med Chem; 2011 Nov; 19(21):6196-202. PubMed ID: 21975067
[TBL] [Abstract][Full Text] [Related]
2. Binding of curcumin and its long chain derivatives to the activator binding domain of novel protein kinase C.
Majhi A; Rahman GM; Panchal S; Das J
Bioorg Med Chem; 2010 Feb; 18(4):1591-8. PubMed ID: 20100661
[TBL] [Abstract][Full Text] [Related]
3. Alkyl cinnamates as regulator for the C1 domain of protein kinase C isoforms.
Mamidi N; Gorai S; Sahoo J; Manna D
Chem Phys Lipids; 2012 Apr; 165(3):320-30. PubMed ID: 22414757
[TBL] [Abstract][Full Text] [Related]
4. Development of diacyltetrol lipids as activators for the C1 domain of protein kinase C.
Mamidi N; Gorai S; Mukherjee R; Manna D
Mol Biosyst; 2012 Apr; 8(4):1275-85. PubMed ID: 22301880
[TBL] [Abstract][Full Text] [Related]
5. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease?
Narlawar R; Pickhardt M; Leuchtenberger S; Baumann K; Krause S; Dyrks T; Weggen S; Mandelkow E; Schmidt B
ChemMedChem; 2008 Jan; 3(1):165-72. PubMed ID: 17943713
[TBL] [Abstract][Full Text] [Related]
6. Selective Modulation of Protein Kinase C α over Protein Kinase C ε by Curcumin and Its Derivatives in CHO-K1 Cells.
Pany S; Majhi A; Das J
Biochemistry; 2016 Apr; 55(14):2135-43. PubMed ID: 26983836
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and protein kinase C (PKC)-C1 domain binding properties of diacyltetrol based anionic lipids.
Mamidi N; Panda S; Borah R; Manna D
Mol Biosyst; 2014 Nov; 10(11):3002-13. PubMed ID: 25190464
[TBL] [Abstract][Full Text] [Related]
8. Recent Updates in Curcumin Pyrazole and Isoxazole Derivatives: Synthesis and Biological Application.
Mishra S; Patel S; Halpani CG
Chem Biodivers; 2019 Feb; 16(2):e1800366. PubMed ID: 30460748
[TBL] [Abstract][Full Text] [Related]
9. Curcumin recognizes a unique binding site of tubulin.
Chakraborti S; Das L; Kapoor N; Das A; Dwivedi V; Poddar A; Chakraborti G; Janik M; Basu G; Panda D; Chakrabarti P; Surolia A; Bhattacharyya B
J Med Chem; 2011 Sep; 54(18):6183-96. PubMed ID: 21830815
[TBL] [Abstract][Full Text] [Related]
10. Lack of nucleophilic addition in the isoxazole and pyrazole diketone modified analogs of curcumin; implications for their antitumor and chemosensitizing activities.
Labbozzetta M; Baruchello R; Marchetti P; Gueli MC; Poma P; Notarbartolo M; Simoni D; D'Alessandro N
Chem Biol Interact; 2009 Sep; 181(1):29-36. PubMed ID: 19539615
[TBL] [Abstract][Full Text] [Related]
11. Structure of the C2 domain from novel protein kinase Cepsilon. A membrane binding model for Ca(2+)-independent C2 domains.
Ochoa WF; Garcia-Garcia J; Fita I; Corbalan-Garcia S; Verdaguer N; Gomez-Fernandez JC
J Mol Biol; 2001 Aug; 311(4):837-49. PubMed ID: 11518534
[TBL] [Abstract][Full Text] [Related]
12. Effects of ortho substituent groups of protocatechualdehyde derivatives on binding to the C1 domain of novel protein kinase C.
Mamidi N; Borah R; Sinha N; Jana C; Manna D
J Phys Chem B; 2012 Sep; 116(35):10684-92. PubMed ID: 22861150
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the C1A and C1B domains to the membrane interaction of protein kinase C.
Giorgione J; Hysell M; Harvey DF; Newton AC
Biochemistry; 2003 Sep; 42(38):11194-202. PubMed ID: 14503869
[TBL] [Abstract][Full Text] [Related]
14. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.
Changtam C; Hongmanee P; Suksamrarn A
Eur J Med Chem; 2010 Oct; 45(10):4446-57. PubMed ID: 20691508
[TBL] [Abstract][Full Text] [Related]
15. Stable and potent analogues derived from the modification of the dicarbonyl moiety of curcumin.
Chakraborti S; Dhar G; Dwivedi V; Das A; Poddar A; Chakraborti G; Basu G; Chakrabarti P; Surolia A; Bhattacharyya B
Biochemistry; 2013 Oct; 52(42):7449-60. PubMed ID: 24063255
[TBL] [Abstract][Full Text] [Related]
16. Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitors.
Nakamura T; Sato M; Kakinuma H; Miyata N; Taniguchi K; Bando K; Koda A; Kameo K
J Med Chem; 2003 Dec; 46(25):5416-27. PubMed ID: 14640550
[TBL] [Abstract][Full Text] [Related]
17. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
Di Fiore A; Pedone C; D'Ambrosio K; Scozzafava A; De Simone G; Supuran CT
Bioorg Med Chem Lett; 2006 Jan; 16(2):437-42. PubMed ID: 16290146
[TBL] [Abstract][Full Text] [Related]
18. Azomethines, isoxazole, N-substituted pyrazoles and pyrimidine containing curcumin derivatives: Urease inhibition and molecular modeling studies.
Ahmed M; Qadir MA; Hameed A; Arshad MN; Asiri AM; Muddassar M
Biochem Biophys Res Commun; 2017 Aug; 490(2):434-440. PubMed ID: 28623137
[TBL] [Abstract][Full Text] [Related]
19. Molecular interaction model for the C1B domain of protein kinase C-gamma in the complex with its activator phorbol-12-myristate-13-acetate in water solution and lipid bilayer.
Hritz J; Ulicny J; Laaksonen A; Jancura D; Miskovsky P
J Med Chem; 2004 Dec; 47(26):6547-55. PubMed ID: 15588090
[TBL] [Abstract][Full Text] [Related]
20. Indolactam and benzolactam compounds as new medicinal leads with binding selectivity for C1 domains of protein kinase C isozymes.
Irie K; Nakagawa Y; Ohigashi H
Curr Pharm Des; 2004; 10(12):1371-85. PubMed ID: 15134488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
